logo-loader
viewImmuPharma PLC

ImmuPharma extends exclusivity period for its collaboration talks with Incanthera

ImmuPharma and Incanthera are making good progress in finalising the definitive licence agreement

Cogs of collaboration
The wheels are turning but it has not been possible to complete negotiations by the deadline

The exclusivity agreement between ImmuPharma PLC (LON:IMM) and Incanthera Limited, due to expire at midnight today, has been extended to the end of March.

ImmuPharma announced on 7 September a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera, but it has yet to finalise the definitive licence agreement'.

REA: ImmuPharma says managed access programme for Lupozor progressing as planned

It is now envisaged that the agreement will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019,” said Dimitri Dimitriou, the chief executive officer of ImmuPharma.

Quick facts: ImmuPharma PLC

Price: 7.85 GBX

AIM:IMM
Market: AIM
Market Cap: £13.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19

2 min read